Pelthos Therapeutics News and Activities

Pelthos Therapeutics is owned by Ligand Pharmaceuticals.

Ligand Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Ligand Pharmaceuticals is a company listed under the stock ticker LGND (US).

Ligand Pharmaceuticals has 3 subsidiaries including Captisol, Channel Therapeutics and Pelthos Therapeutics.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Ligand Pharmaceuticals.

• Xoma Royalty and Ligand Pharmaceuticals have announced they will merge  (posted on April 27 2026)..

View the org chart displaying its 30 main executives

Most searched biographies at Pelthos Therapeutics

• Scott Plesha, Chief Executive Officer
• Matt Pauls, Director
• Ezra Friedberg, Director

Popular executive movements at Pelthos Therapeutics

• Erik Winquist, Regional Sales Manager, has left the company  (posted on April 13 2026).
• Benjamin Williams who was Engineering and Procurement Manager, becomes Associate Director, Engineering and Supply Chain  (posted on April 13 2026).
• John Gay, who was Senior Vice President, Finance and Accounting, is promoted to Chief Financial Officer  (posted on April 13 2026).

Click here to view some more movements at Pelthos Therapeutics

Popular executive movements at Ligand Pharmaceuticals

• Peter Renehan has joined the company as Vice President, Investments and Business Development  (posted on April 3 2026).
• Lauren Hay who was Vice President, Strategic Planning and Investment Analytics, becomes Vice President of Portfolio Strategy and Investments  (posted on April 3 2026).
• Lee Brown has joined the company as Vice President, Investments & Business Development  (posted on April 3 2026).

Create your alert
to follow the executive moves at Pelthos Therapeutics.

Ligand Pharmaceuticals has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Pelthos Therapeutics

Social media about Pelthos Therapeutics

• Pelthos Therapeutics on Wikipedia, Google News & Yahoo Finance
• Pelthos Therapeutics on LinkedIn, X (Twitter) & YouTube